<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Motor neurone disease. The use of non-invasive ventilation in the management of motor neurone disease.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Centre for Clinical Practice. Motor neurone disease. The use of non-invasive ventilation in the management of motor neurone disease. London (UK): National Institute for Health and Clinical Excellence (NICE); 2010 Jul. 127 p.&amp;nbsp;(Clinical guideline; no. 105).&amp;nbsp; [53 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Lung involvement in other diseases classified elsewhere  (517.8); Non-invasive mechanical ventilation  (93.90); Other motor neuron disease  (335.29); Unspecified disorders of nervous system  (349.9)"/><FieldValue Value="MSH: Blood Gas Analysis ; Dementia ; Motor Neuron Disease ; Nervous System Diseases ; Oximetry ; Patient Care Planning ; Patient Care Team ; Patient Education as Topic ; Patient-Centered Care ; Respiration, Artificial ; Respiratory Function Tests ; Respiratory Insufficiency ; Risk Assessment ; Social Support ; Terminal Care ; Vital Capacity "/><FieldValue Value="MTH: Blood Gas Analysis ; Caregiver support (regime/therapy) ; Dementia ; nervous system disorder ; Oxygen saturation measurement ; Patient education (procedure) ; Respiratory Function Tests ; Respiratory Insufficiency ; Risk Assessment ; Social support ; terminal patient care ; Vital capacity "/><FieldValue Value="SNOMEDCT_US: Artificial respiration  (40617009); Assisted breathing  (266700009); Blood gas analysis  (167018008); Blood gas analysis  (278297009); Caregiver support  (386229000); Dementia  (52448006); Disorder of nervous system  (118940003); Dying care  (182964004); Dying care  (385736008); Family support  (243115004); Measurement of respiratory function  (23426006); Motor neuron disease  (37340000); Oxygen saturation measurement  (104847001); Oxygen saturation measurement  (264598005); Patient education  (311401005); Personal risk assessment done  (407658003); Pulse oximeter  (448703006); Pulse oximetry  (252465000); Pulse oximetry  (708065004); Respiratory insufficiency  (409623005); Risk assessment  (225338004); Vital capacity  (268379003)"/><FieldValue Value="SPN: METER, AIRWAY PRESSURE (INSPIRATORY FORCE) "/><FieldValue Value="UMD: Analyzers, Laboratory, Blood Gas  (18-617); Manometers, Inspiratory Pressure  (13-109); Oximeters, Pulse  (17-148); Physiologic Monitor Modules, Pulse Oximetry  (20-781)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Motor neurone disease&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Counseling" /><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Family Practice" /><FieldValue Value="Geriatrics" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Neurology" /><FieldValue Value="Nursing" /><FieldValue Value="Physical Medicine and Rehabilitation" /><FieldValue Value="Pulmonary Medicine" /><FieldValue Value="Speech-Language Pathology" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Nurses" /><FieldValue Value="Physical Therapists" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /><FieldValue Value="Respiratory Care Practitioners" /><FieldValue Value="Speech-Language Pathologists" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To improve the care and quality of life of people with motor neurone disease (MND) by making evidence-based recommendations on the use of non-invasive ventilation in the management of MND&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Adults (aged 18 and over) with a diagnosis of&amp;nbsp;motor neurone disease (MND)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Evaluation/Assessment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Identify multidisciplinary team &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Provide information and support needs to patients with motor neurone disease (MND) and their families and carers &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Respiratory function tests&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Oxygen saturation measured by pulse oximetry (SpO&lt;sub&gt;2&lt;/sub&gt;) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Forced vital capacity (FVC) or vital capacity (VC) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Sniff nasal inspiratory pressure (SNIP) and/or maximal inspiratory pressure (MIP) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Arterial or capillary blood gas analysis &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Referral to pulmonary specialist &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Treatment/Management&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Discuss both the benefits and limitations of non-invasive ventilation (NIV) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Conduct patient-centered risk assessment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Prepare a comprehensive care plan &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Initiation and continuation of NIV&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Perform pre-treatment assessment of patients with diagnosis of dementia &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Planning end-of-life care &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Diagnostic accuracy of investigations for detecting and monitoring respiratory impairment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Symptom relief (such as sleep disturbance and respiratory function) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Tolerance and adherence &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adverse events of non-invasive ventilation (NIV) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Frequency and duration of hospitalisation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Quality of Life &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Morbidity &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mortality &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cost-effectiveness &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Note from the National Guideline Clearinghouse (NGC)&lt;/strong&gt;: This guideline was developed by the Centre for Clinical Practice at the National Institute for Health and Clinical Excellence (NICE).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Scoping Searches&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Scoping searches were undertaken in June 2009 using the following websites and databases (listed in alphabetical order); browsing or simple search strategies were employed. The search results were used to provide information for scope development and project planning.&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Scoping Searches&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Guidance/Guidelines&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Systematic Reviews/Economic Evaluations&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;ALS Association&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;ALS Forums&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;ALS Society of Canada&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Association of British Neurologists&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Association of Chartered Physiotherapists Interested in Neurology (ACPIN)&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Brain and Spine Foundation&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;build-uk.net (Building a motor neurone disease network for the UK)&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Canadian Medical Association Infobase &lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Clinical Knowledge Summaries&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Department of Health&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Focus on ALS&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Guidelines International Network (GIN)&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;International Alliance of ALS/MND Associations&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Living with ALS&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Motor Neurone Disease (MND) Association&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Motor Neurone Disease Association of Northern Ireland, MND - MNDANI&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Motor Neurone Disease (MND) Care and Research Centre&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Motor Neurone Disease (MND) Scotland&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;National Guideline Clearinghouse (US)&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;National Health and Medical Research Council (Australia)&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;National Institute for Health and Clinical Excellence (NICE) &amp;ndash; guidance published &amp;amp; in development&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;National Institute for Health and Clinical Excellence (NICE) &amp;ndash; topic selection&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;National Institute of Neurological Disorders and Stroke (NINDS)&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Neurological Alliance&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;NHS Evidence &amp;ndash; National Library of Guidelines&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;NHS Evidence - Specialist Collections&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;New Zealand Guidelines Group&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Royal College of Anesthetists&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Royal College of General Practitioners&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Royal College of Nursing&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Royal College of Physicians&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Royal College of Psychiatrists&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Royal College of Surgeons&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Royal Hospital for Neuro-disability&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Scottish Intercollegiate Guidelines Network (SIGN)&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;The Society of British Neurological Surgeons&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;World Federation of ALS/Neurology website&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Clinical Evidence&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Cochrane Database of Systematic Reviews (CDSR)&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Database of Abstracts of Reviews of Effects (DARE)&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Health Economic Evaluations Database (HEED)&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Health Technology Assessment (HTA) Database&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;NHS Economic Evaluation Database (NHS EED)&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;NHS R&amp;amp;D Service Delivery and Organisation (NHS SDO) Program&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;National Institute for Health Research (NIHR) Health Technology Assessment Programme&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;TRIP Database&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Main Searches&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The following sources were searched for the topics presented in the sections below.&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Cochrane Database of Systematic Reviews &amp;ndash; CDSR (Wiley) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cochrane Central Register of Controlled Trials &amp;ndash; CENTRAL (Wiley) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Database of Abstracts of Reviews of Effects &amp;ndash; DARE (Wiley) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Health Technology Assessment Database &amp;ndash; HTA (Wiley) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;CINAHL (EBSCO and NHS Evidence - Search 2.0) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;EMBASE (Ovid) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;MEDLINE (Ovid) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;MEDLINE In-Process (Ovid) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;PsycINFO (Ovid) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;The MEDLINE search strategy was translated for use in all of the other databases. Detailed information on the search strategy can be found in Appendix 9.1 of the original guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Health Economics&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The following sources were searched to identify economic evaluations and quality of life data relating to the identification of signs and symptoms in patients with motor neurone disease (MND), and the clinical effectiveness and cost-effectiveness of non-invasive ventilation (NIV) for respiratory impairment in people with MND.&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Health Economic Evaluations Database &amp;ndash; HEED (Wiley) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;NHS Economic Evaluation Database &amp;ndash; NHS EED (Wiley and CRD website) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;EMBASE (Ovid) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;MEDLINE (Ovid) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;MEDLINE In-Process (Ovid) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Expert Consensus" /><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review with Evidence Tables" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Note from the National Guideline Clearinghouse (NGC)&lt;/strong&gt;: This guideline was developed by the Centre for Clinical Practice at the National Institute for Health and Clinical Excellence (NICE).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Studies that met inclusion criteria (see Appendix 9.2 in the original guideline) were appraised using GRADE (Grading of Recommendations Assessment, Development and Evaluation) profiles (for the methodology of GRADE, see Appendix 9.2 in the original guideline), and evidence statements were drawn to further summarise the evidence and evidence statements were drawn to further summarize the evidence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See section 2.1 of the original guideline for details of the evidence reviews.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Note from the National Guideline Clearinghouse (NGC)&lt;/strong&gt;: This guideline was developed by the Centre for Clinical Practice at the National Institute for Health and Clinical Excellence (NICE).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For a full explanation of how this type of guideline was developed, see 'The guidelines manual' (2009) at &lt;a href=&quot;http://www.nice.org.uk/GuidelinesManual&quot; title=&quot;NICE Web site&quot;&gt;www.nice.org.uk/GuidelinesManual&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Health Economic Modelling&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Two models were developed to estimate the cost effectiveness of non-invasive ventilation (NIV): the first was based on a Markov model and the second was based on a randomised control trial (RCT). The following criteria were used for both models:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The estimate of the efficacy of NIV in patients with motor neurone disease (MND) (that is, the percentage of patients with MND who can tolerate NIV) was based on the results of a RCT of the effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis and adjusted based on reported tolerance in other studies and the experience of Guideline Development Group (GDG) members. See Appendix 9.7 in the original guideline for more details. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients accrued costs and utilities depending on their pathway through the model. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Costs were obtained from National Health Service (NHS) reference costs and published papers. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Costs of equipment such as ventilator machines were obtained from GDG expert opinion. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;There was no information from either the literature or GDG members on the costs or quality-of-life outcomes resulting from adverse events of NIV. More details of the rationale for both models, the efficacy of NIV, and chosen utilities and costs are presented in Appendix 9.7 in the original guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Markov Model&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This first model was based on a decision-analytic methodology using Markov-modelling-based transition probabilities obtained from a Health Technology Assessment (HTA) report. This HTA report assumed that patients with MND can progress and regress in a stepwise manner through the model. However, the GDG considered that patients can only progress and cannot revert to an earlier health state in the model.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Disease-specific health states were defined and transition probabilities were assigned for movement between the health states over a discrete time period (or Markov cycle). Once the model structure (health states, transitions) was set, estimates of resource use and health outcomes associated with the states and transitions between states in the model were incorporated. EQ-5D utilities were obtained from published sources that linked quality of life to progression of MND.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;RCT Model&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The second economic model was designed to closely reflect an RCT of the effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis, which investigated the effects of NIV on survival and quality of life in patients with MND. Patients diagnosed with MND with respiratory failure received no NIV (current best practice; n = 19) or NIV (n = 22). Death was the absorbing state in both arms. Data on quality of life obtained using Short-Form (SF)-36 from the RCT of the effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis were converted into EQ-5D values using a mapping technique.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Types of Analysis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Using the Markov model, both deterministic analysis (using only point estimates) and probabilistic analysis (using a range of values and simulation to account for uncertainty) were conducted to examine cost-effectiveness. Additional analysis included cost-effectiveness acceptability curves, which assess the probability that a treatment or intervention is cost effective at a particular cost per quality-adjusted life-year (QALY) gained &amp;ndash; in this case 30,000 pounds per QALY. Finally, value of information analysis was conducted, which places a monetary value on how much it is worth to society to resolve the uncertainty in the cost-effectiveness analysis by conducting further research.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Results&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The results of the cost-effectiveness analysis using the Markov model are summarised in the table below.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Results of Cost-effectiveness Analysis of NIV Using a Markov Model&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Results of Cost-effectiveness Analysis of NIV Using a Markov Model&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Comparison&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Deterministic ICER (per QALY gained)&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Probability of Being Cost Effective at &amp;pound;30,000 per QALY&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;No NIV vs NIV&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;pound;34,639&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;12.7%&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Standard care vs NIV&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;pound;21,556&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;90%&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;3&quot;&gt;&#xD;&#xA;            &lt;p class=&quot;Note&quot;&gt;ICER, incremental cost-effectiveness ratio; NIV, non-invasive ventilation; QALY, quality-adjusted life year&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;The figure obtained from the value of information analysis was approximately 40 million pounds. This represents the amount that society would be willing to pay to resolve uncertainty in the cost-effectiveness analysis by undertaking further research on the use of NIV in patients with MND (see Appendix 9.7 in the original guideline for more details of value of Information analysis).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;ICERs were obtained using the RCT model by calculating the cost difference and QALY gain obtained when comparing the NIV and No NIV strategies. The base-case ICERs were between 13,327 and 30,439 pounds per QALY gained when the 'No NIV' quality-of-life profile was varied. Appendix 9.7 gives details of a deterministic sensitivity analysis in which cost and QALYs were varied for the 'No NIV' strategy.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The evidence presented indicates that NIV is cost-effective in a modelled population. However, there is considerable uncertainty around the estimates, and so the results should be interpreted with caution. The RCT model in particular is highly speculative. Nonetheless, together with the available evidence, the results are useful and give indications to inform the GDG.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Discussion&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The GDG discussed the cost-effectiveness results from the two analyses presented. The GDG noted that the Markov model was based on robust methodology and data and that it was of high quality. However, the GDG had concerns that the structure of the Markov model did not accurately capture an improvement in quality of life, and so may underestimate the quality-of-life benefits attributable to NIV. The GDG also noted that the RCT model lacked data on quality of life after randomisation for some subjects because of early deaths in the 'No NIV' arm before the scheduled quality of-life-assessment. The GDG was mindful that the results of the RCT model were highly speculative. The GDG also noted that a limitation of both models was the instruments used to capture quality of life (SF-36 and EQ-5D), which are highly insensitive to the symptoms of MND. The GDG concluded that the ICER estimates obtained using the Markov model were on the high side, although they did indicate that NIV is cost effective, since more accurate capturing of the quality of life would reduce the ICERs much further. Therefore, given the severity of MND, the lack of alternative treatment options for respiratory impairment and the difficulty in measuring quality of life in patients with MND, the GDG considered that the use of NIV in the management of people with MND represents a cost-effective use of NHS resources.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The guideline was validated through two consultations.&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The first draft of the guideline (the full guideline and Quick Reference Guide) were consulted with stakeholders and comments were considered by the Guideline Development Group (GDG). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The final consultation draft of the full guideline and the Information for the Public were submitted to stakeholders for final comments. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;The final draft was submitted to the Guideline Review Panel for review prior to publication.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Note from the National Guideline Clearinghouse (NGC)&lt;/strong&gt;: This guideline was developed by the Centre for Clinical Practice at the National Institute for Health and Clinical Excellence (NICE).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Multidisciplinary Team&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A multidisciplinary team should coordinate and provide ongoing management and treatment for a patient with motor neurone disease (MND), including regular respiratory assessment and provision of non-invasive ventilation.&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The team should be led by a healthcare professional with a specific interest in MND. The leader should ensure that the patient's multidisciplinary care plan (see recommendation below, 'Before starting Non-invasive Ventilation') is coordinated and is communicated to relevant healthcare and social care professionals, including the patient's primary care team, as well as to the patient and (where appropriate) their family and carers. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The team should include a neurologist, a respiratory physician, an MND specialist nurse, a respiratory specialist nurse, a specialist respiratory physiotherapist, a respiratory physiologist, a specialist in palliative care and a speech and language therapist (team members do not have to be at the same location). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Access to other healthcare professionals should be provided as needed. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Team members who provide non-invasive ventilation should have appropriate competencies. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Information and Support Needs of Patients with MND and Their Families and Carers&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Offer to discuss the possible use of non-invasive ventilation with the patient and (if the patient agrees) their family and carers, at an appropriate time and in a sensitive manner. This may be at one or more of the following times:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Soon after MND is first diagnosed &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;When monitoring respiratory function &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;When respiratory function deteriorates &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If the patient asks for information &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Discussions should be appropriate to the stage of the patient's illness, carried out in a sensitive manner and include information on:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The possible symptoms and signs of respiratory impairment (see Table 1 below) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The natural progression of MND and what to expect in the future &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The purpose, nature and timing of respiratory function tests, and explanations of the test results &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Available interventions for managing respiratory impairment, including the benefits and limitations of each intervention &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Accessing and using respiratory equipment, including that for non-invasive ventilation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;How non-invasive ventilation (as a treatment option) can improve symptoms associated with respiratory impairment and can be life prolonging, but does not stop progression of the underlying disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;How non-invasive ventilation can be withdrawn &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Palliative strategies as an alternative to non-invasive ventilation &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Inform all relevant healthcare professionals about key decisions reached with the patient and their family and carers.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Provide the patient and their family and carers with support and assistance to manage non-invasive ventilation. This should include:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Training on using non-invasive ventilation and ventilator interfaces, for example:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Emergency procedures &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Night-time assistance if the patient is unable to use the equipment independently (for example, emergency removal or replacement of interfaces) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;How to use the equipment with a wheelchair or other mobility aids if required &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;What to do if the equipment fails &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assistance with secretion management &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Information on general palliative strategies &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;An offer of ongoing emotional and psychological support for the patient and their family and carers (see the NICE guidance, &lt;a href=&quot;http://guidance.nice.org.uk/CSGSP&quot; title=&quot;NICE Web site&quot;&gt;Improving supportive and palliative care for adults with cancer&lt;/a&gt; [Cancer service guidance; CSGSP]) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Ensure that families and carers:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Have an initial assessment if the patient they care for decides to use non-invasive ventilation, which should include:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Their ability and willingness to assist in providing non-invasive ventilation &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Their training needs &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Have the opportunity to discuss any concerns they may have with members of the multidisciplinary team and/or other healthcare professionals. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Identification and Assessment of Respiratory Impairment in Patients with MND&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Symptoms and Signs&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Monitor the symptoms and signs listed in Table 1 (below) routinely to detect potential respiratory impairment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Table 1. Symptoms and Signs of Potential Respiratory Impairment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table 1. Symptoms and Signs of Potential Respiratory Impairment&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Symptoms&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Signs&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Breathlessness&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Orthopnoea&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Recurrent chest infections&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Disturbed sleep&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Non-refreshing sleep&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Nightmares&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Daytime sleepiness&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Poor concentration and/or memory&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Confusion&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Hallucinations&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Morning headaches&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Fatigue&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Poor appetite&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;p&gt;Increased respiratory rate&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Shallow breathing&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Weak cough*&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Weak sniff&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Abdominal paradox (inward movement of the abdomen during inspiration)&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Use of accessory muscles of respiration&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Reduced chest expansion on maximal inspiration&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*Weak cough could be assessed by measuring cough peak flow.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Respiratory Function Tests&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;As part of the initial assessment to diagnose MND, or soon after diagnosis, a healthcare professional from the multidisciplinary team who has appropriate competencies should perform the following tests (or arrange for them to be performed) to establish the patient's baseline respiratory function:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Oxygen saturation measured by pulse oximetry (SpO&lt;sub&gt;2&lt;/sub&gt;):&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;This should be a single measurement of SpO&lt;sub&gt;2&lt;/sub&gt; with the patient at rest and breathing room air &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;If it is not possible to perform pulse oximetry locally, refer the patient to a specialist respiratory service &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Then one or both of the following:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Forced vital capacity (FVC) or vital capacity (VC)** &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Sniff nasal inspiratory pressure (SNIP) and/or maximal inspiratory pressure (MIP) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;**The difference between the measurement of vital capacity and forced vital capacity is very subtle, and so either can be used.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;If the patient has severe bulbar impairment or severe cognitive problems that may be related to respiratory impairment:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Ensure that SpO&lt;sub&gt;2&lt;/sub&gt; is measured (at rest and breathing room air) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Do not perform the other respiratory function tests (FVC, VC, SNIP and MIP) if interfaces are not suitable for the patient &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;A healthcare professional with appropriate competencies should perform the respiratory function tests every 3 months, although tests may be performed more or less often depending on:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Whether there are any symptoms and signs of respiratory impairment (see recommendation above, 'Symptoms and Signs') &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The rate of progression of MND &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The patient's preference and circumstances &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Perform arterial or capillary blood gas analysis if the patient's SpO&lt;sub&gt;2&lt;/sub&gt; (measured at rest and breathing room air):&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Is less than or equal to 92% if they have known lung disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Is less than or equal to 94% if they do not have lung disease &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;If it is not possible to perform arterial or capillary blood gas analysis locally, refer the patient to a specialist respiratory service.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;If the patient's SpO&lt;sub&gt;2&lt;/sub&gt; (measured at rest and breathing room air) is greater than 94%, or 92% for those with lung disease, but they have sleep-related respiratory symptoms:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Consider referring them to a specialist respiratory service for nocturnal (overnight) oximetry and/or a limited sleep study &lt;strong&gt;and&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Discuss both the impact of respiratory impairment and treatment options with the patient and (if the patient agrees) their family and carers. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;If the patient's arterial partial pressure of carbon dioxide (PaCO&lt;sub&gt;2&lt;/sub&gt;) is greater than 6 kPa:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Refer them urgently to a specialist respiratory service (to be seen within 1 week) &lt;strong&gt;and&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Explain the reasons for and implications of the urgent referral to the patient and (if the patient agrees) their family and carers. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;If the patient's PaCO&lt;sub&gt;2&lt;/sub&gt; is less than or equal to 6 kPa but they have any symptoms or signs of respiratory impairment, particularly orthopnoea (see recommendation above, 'Symptoms and Signs'):&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Refer them to a specialist respiratory service for nocturnal (overnight) oximetry and/or a limited sleep study &lt;strong&gt;and&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Discuss both the impact of respiratory impairment and treatment options with the patient and (if the patient agrees) their family and carers. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;If any of the results listed in Table 2 (below) is obtained, discuss with the patient and (if the patient agrees) their family and carers:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The impact of respiratory impairment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment options &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Possible referral to a specialist respiratory service for further assessment &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Table 2. Results of Respiratory Function Tests&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table 2. Results of Respiratory Function Tests&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;Forced Vital Capacity (FVC) or Vital Capacity (VC)&lt;/strong&gt;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;Sniff Nasal Inspiratory Pressure (SNIP) and/or Maximal Inspiratory Pressure (MIP)&lt;/strong&gt; &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            &lt;em&gt;(if both tests are performed, base the assessment on the better respiratory function reading)&lt;/em&gt; &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;FVC or VC less than 50% of predicted value &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;FVC or VC less than 80% of predicted value plus any symptoms or signs of respiratory impairment (see recommendation, 'Symptoms and Signs'), particularly orthopnoea &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;SNIP or MIP less than 40 cmH&lt;sub&gt;2&lt;/sub&gt;O &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;SNIP or MIP less than 65 cmH&lt;sub&gt;2&lt;/sub&gt;O for men or 55 cmH&lt;sub&gt;2&lt;/sub&gt;O for women plus any symptoms or signs of respiratory impairment (see recommendation, 'Symptoms and Signs'), particularly orthopnoea &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Repeated regular tests show a rate of decrease of SNIP or MIP of more than 10 cmH&lt;sub&gt;2&lt;/sub&gt;O per 3 months &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Patients with a Diagnosis of Dementia&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Base decisions on respiratory function tests for a patient with a diagnosis of dementia on considerations specific to their needs and circumstances, such as:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Their ability to give consent (see the NICE guideline, 'Dementia: supporting people with dementia and their carers in health and social care' [NICE clinical guidance 42]) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Their understanding of the tests &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Their tolerance of the tests and willingness to undertake them &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The impact on their family and carers &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Whether they are capable of receiving non-invasive ventilation &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Non-invasive Ventilation for Treatment of Respiratory Impairment in Patients with MND&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Offer a trial of non-invasive ventilation if the patient's symptoms and signs and the results of the respiratory function tests indicate that the patient is likely to benefit from the treatment.&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Discuss both the benefits and limitations of the intervention with the patient and their family and carers. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Only consider a trial of non-invasive ventilation for a patient who has severe bulbar impairment or severe cognitive problems that may be related to respiratory impairment if they may benefit from an improvement in sleep-related symptoms or correction of hypoventilation. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Before starting non-invasive ventilation, the multidisciplinary team should carry out and coordinate a patient-centred risk assessment, after discussion with the patient and their family and carers. This should consider:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The most appropriate type of non-invasive ventilator and interfaces, based on the patient's needs and lifestyle factors &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The patient's tolerance of the treatment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The risk, and possible consequences, of ventilator failure &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The power supply required, including battery back-up &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;How easily the patient can get to hospital &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Risks associated with travelling away from home (especially abroad) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Whether a humidifier is required &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Issues relating to secretion management &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The availability of carers &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Before starting non-invasive ventilation, the multidisciplinary team should prepare a comprehensive care plan, after discussion with the patient and their family and carers (who should be offered a copy of the plan). This should cover:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Long-term support provided by the multidisciplinary team &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The initial frequency of respiratory function tests and monitoring of respiratory impairment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The frequency of clinical reviews of symptomatic and physiological changes &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The provision of carers &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Arrangements for device maintenance and 24-hour emergency clinical and technical support &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Secretion management and respiratory physiotherapy assessment, including cough-assist therapy (if required) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Training in and support for the use of non-invasive ventilation for the patient and their family and carers &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Regular opportunities to discuss the patient's wishes in relation to continuing or withdrawing non-invasive ventilation, and other end-of-life considerations (see also recommendations below, 'Planning End-of-life Care'). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;When starting non-invasive ventilation:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Perform initial acclimatisation during the day when the patient is awake &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Usually start regular treatment at night, before and during sleep &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Gradually build up the patient's hours of use as necessary &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Continue non-invasive ventilation if the clinical reviews show:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Symptomatic and/or physiological improvements for a patient without severe bulbar impairment and without severe cognitive problems &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;An improvement in sleep-related symptoms for a patient with severe bulbar impairment or with severe cognitive problems that may be related to respiratory impairment &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Discuss all decisions to continue or withdraw non-invasive ventilation with the patient and (if the patient agrees) their family and carers.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Patients with a Diagnosis of Dementia&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Before a decision is made on the use of non-invasive ventilation for a patient with a diagnosis of dementia, the neurologist from the multidisciplinary team should carry out an assessment that includes:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The patient's capacity to make decisions and to give consent (see the NICE guideline, 'Dementia: supporting people with dementia and their carers in health and social care' [NICE clinical guidance 42]) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The severity of dementia and cognitive problems &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Whether the patient is likely to accept treatment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Whether the patient is likely to achieve improvements in sleep-related symptoms and/or behavioural improvements &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A discussion with the patient's family and/or carers (with the patient's consent if they have the capacity to give it) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Planning End-of-life Care&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Offer to discuss end-of-life care with the patient and (if the patient agrees) their family and carers, at an appropriate time and in a sensitive manner. This may be at one or more of the following times:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Around the time that MND is first diagnosed (but only if requested by the patient explicitly, or if the patient's clinical condition indicates that ventilator support will be needed in the immediate future) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;When non-invasive ventilation is accepted or declined &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;When the patient is becoming increasingly dependent on non-invasive ventilation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If the patient asks for information &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Discussions about end-of-life care should include:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Planning of end-of-life care &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Considering advance decisions to refuse treatment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Considering what to do if non-invasive ventilation fails because of either:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;An acute, but potentially reversible, deterioration in health &lt;strong&gt;or&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Irreversible disease progression &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Strategies to withdraw non-invasive ventilation if the patient wishes &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The involvement of family and carers in decision making (with the patient's consent if they have the capacity to give it). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Care pathways for the assessment of respiratory function and non-invasive ventilation are provided in the original guideline.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is not specifically stated for each recommendation.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendations are based on clinical and cost-effectiveness evidence, and where this is insufficient, the Guideline Development Group (GDG) used all available information sources and experience to make consensus recommendations.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Safe and effective use of non-invasive ventilation&amp;nbsp;in the management of patients with motor neurone disease&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;People with motor neurone disease who have significant bulbar involvement may have lower tolerance of non-invasive ventilation compared with people with little or no bulbar muscle weakness.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;This guidance represents the view of National Institute for Health and Clinical Excellence (NICE), which was arrived at after careful consideration of the evidence available. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer, and informed by the summary of product characteristics of any drugs they are considering. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have regard to promoting equality of opportunity. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment and care should take into account patients' needs and preferences. People with MND should have the opportunity to make informed decisions about their care and treatment, in partnership with their healthcare professionals. If patients do not have the capacity to make decisions, healthcare professionals should follow the Department of Health's advice on consent (available from &lt;a href=&quot;http://www.dh.gov.uk/consent&quot; title=&quot;UK DoH Web site&quot;&gt;www.dh.gov.uk/consent&lt;/a&gt;) and the code of practice that accompanies the Mental Capacity Act (summary available from &lt;a href=&quot;http://www.publicguardian.gov.uk&quot; title=&quot;UK Public Guardian Web site&quot;&gt;www.publicguardian.gov.uk&lt;/a&gt;). In Wales, healthcare professionals should follow advice on consent from the Welsh Assembly Government (available from &lt;a href=&quot;http://www.wales.nhs.uk/consent&quot; title=&quot;Wales DoH Web site&quot;&gt;www.wales.nhs.uk/consent&lt;/a&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Audit Criteria/Indicators" /><FieldValue Value="Clinical Algorithm" /><FieldValue Value="Foreign Language Translations" /><FieldValue Value="Patient Resources" /><FieldValue Value="Quick Reference Guides/Physician Guides" /><FieldValue Value="Resources" /><FieldValue Value="Slide Presentation" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="End of Life Care" /><FieldValue Value="Living with Illness" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Centre for Clinical Practice. Motor neurone disease. The use of non-invasive ventilation in the management of motor neurone disease. London (UK): National Institute for Health and Clinical Excellence (NICE); 2010 Jul. 127 p.&amp;nbsp;(Clinical guideline; no. 105).&amp;nbsp; [53 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2010 Jul" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="National Institute for Health and Care Excellence (NICE) - National Government Agency [Non-U.S.]" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;National Institute for Health and Clinical Excellence (NICE)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Guideline Development Group&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Guideline Development Group&lt;/em&gt;: Gary McVeigh (&lt;em&gt;Chair&lt;/em&gt;), Consultant Physician, Belfast trust and Professor of Medicine, Queens University Belfast; Kenneth Allott, Patient and carer member; Robert Angus, Consultant Physician in Respiratory and High Dependency Medicine, University Hospital Aintree; Stephen Bourke, Consultant Physician in Respiratory and General Medicine, Northumbria Healthcare NHS Foundation Trust; Pauline Callagher, MND Care &amp;amp; Research Center Co-ordinator, Royal Preston Hospital; Una Carlow, Patient and carer member; Mark Elliott, Consultant Physician in Respiratory and General Medicine, St James's University Hospital, Leeds; Natalie Laine, Patient and carer member; Heidi Macleod, Patient and carer member; Chris McDermott, Clinical Senior Lecturer and Honorary Consultant Neurologist, Royal Hallamshire Hospital; Christine Mikelsons, Consultant Respiratory Physiotherapist, Royal Free Hospital, London; Alan Moore, Professional Clinical Services Manager &amp;amp; Head of Respiratory Physiology, Sandwell &amp;amp; West Birmingham Hospitals NHS Trust; David Oliver, Consultant in Palliative Medicine, Wisdom Hospice, Rochester and Honorary Senior Lecturer, University of Kent; Aleksandar Radunovic, Consultant Neurologist, Royal London Hospital and Queen's Hospital, Romford; Greg Rogers, Clinical Commissioner for Long Term Conditions for Eastern and Coastal Kent PCT; Carolyn Young, Consultant Neurologist and Honorary Professor of Neurology, Walton Center for Neurology &amp;amp; Neurosurgery&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A full list of all declarations of interest made by this Guideline Development Group is available on the &lt;a href=&quot;http://www.nice.org.uk/&quot; title=&quot;NICE Web site&quot;&gt;National Institute for Health and Clinical Excellence (NICE) Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://guidance.nice.org.uk/CG105&quot; title=&quot;NICE Web site&quot;&gt;National Institute for Health and Clinical Excellence (NICE) Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following is available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Motor neurone disease. The use of non-invasive ventilation in the management of motor neurone disease. Quick reference guide. London (UK): National Institute for Health and Clinical Excellence (NICE); 2010 Jul. 12 p. (Clinical guideline; no. 105). Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://guidance.nice.org.uk/CG105/QuickRefGuide/pdf/English&quot; title=&quot;NICE Web site&quot;&gt;National Institute for Health and Clinical Excellence (NICE) Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Non-invasive ventilation in the management of motor neurone disease. Audit support. Implementing NICE guidance. London (UK): National Institute for Health and Clinical Excellence (NICE); 2010 Jul. 16 p. (Clinical guideline; no. 105). Electronic copies: Available from the &lt;a href=&quot;http://guidance.nice.org.uk/CG105/AuditSupport/doc/English&quot; title=&quot;NICE Web site&quot;&gt;NICE Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Non-invasive ventilation in the management of motor neurone disease. Costing report. Implementing NICE guidance. London (UK): National Institute for Health and Clinical Excellence (NICE); 2010 Jul. 27 p. (Clinical guideline; no. 105). Electronic copies: Available in PDF from the &lt;a href=&quot;http://guidance.nice.org.uk/CG105/CostingReport/pdf/English&quot; title=&quot;NICE Web site&quot;&gt;NICE Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Non-invasive ventilation in the management of motor neurone disease. Costing template. Implementing NICE guidance. London (UK): National Institute for Health and Clinical Excellence (NICE); 2010 Jul. 27 p. (Clinical guideline; no. 105). Electronic copies: Available from the &lt;a href=&quot;http://guidance.nice.org.uk/CG105/CostingTemplate/xls/English&quot; title=&quot;NICE Web site&quot;&gt;NICE Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Non-invasive ventilation in the management of motor neurone disease. Slide set. Implementing NICE guidance. London (UK): National Institute for Health and Clinical Excellence (NICE); 2010 Jul. 21 p. (Clinical guideline; no. 105). Electronic copies: Available from the &lt;a href=&quot;http://guidance.nice.org.uk/CG105/SlideSet/ppt/English&quot; title=&quot;NICE Web site&quot;&gt;NICE Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Non-invasive ventilation in the management of motor neurone disease. Baseline assessment tool. Implementing NICE guidance. London (UK): National Institute for Health and Clinical Excellence (NICE); 2010 Jul. (Clinical guideline; no. 105). Electronic copies: Available the &lt;a href=&quot;http://guidance.nice.org.uk/CG105/BaselineAssessment/xls/English&quot; title=&quot;NICE Web site&quot;&gt;NICE Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following is available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Motor neurone disease. The use of non-invasive ventilation in the management of motor neurone disease. Understanding NICE guidance. Information for people who use NHS services. London (UK): National Institute for Health and Clinical Excellence (NICE); 2010 Jul. 12 p. (Clinical guideline; no. 105). Electronic copies: Available in Portable Document Format (PDF) format from the &lt;a href=&quot;http://guidance.nice.org.uk/CG105/PublicInfo/pdf/English&quot; title=&quot;NICE Web site&quot;&gt;National Institute for Health and Clinical Excellence (NICE) Web site&lt;/a&gt;. Also available in Welsh from the &lt;a href=&quot;http://guidance.nice.org.uk/CG105/PublicInfo/doc/Welsh&quot; title=&quot;NICE Web site&quot;&gt;NICE Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p class=&quot;Disclaimer&quot;&gt;Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI on February 4, 2011.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The National Institute for Health and Clinical Excellence (NICE) has granted the National Guideline Clearinghouse (NGC) permission to include summaries of their Technology Appraisal guidance with the intention of disseminating and facilitating the implementation of that guidance. NICE has not verified this content to confirm that it accurately reflects the original NICE guidance and therefore no guarantees are given by NICE in this regard. All NICE technology appraisal guidance is prepared in relation to the National Health Service in England and Wales. NICE has not been involved in the development or adaptation of NICE guidance for use in any other country. The full versions of all NICE guidance can be found at &lt;a href=&quot;http://www.nice.org.uk&quot; title=&quot;NICE Web site&quot;&gt;www.nice.org.uk&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
